MT-601, Marker's lead MAR-T cell therapy, is being evaluated in the nationwide multicenter Phase 1 APOLLO study ( clinicaltrials.gov identifier: NCT05798897) in patients with anti-CD19 CAR-T relapsed ...
Sphere Bio's Cyto-Cellect Assay Kit integrates viability and antibody detection, streamlining workflows and ensuring optimal selection of high-producing clones.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback